Medindia LOGIN REGISTER
Medindia

Icatibant Interaction with other Drugs


Icatibant is a peptidomimetic agent, prescribed for Hereditary Angioedema (HAE).

Icatibant Interaction with 405 drugs. Find out more in the list below:

Abciximab


Icatibant may increase the anticoagulant activities of Abciximab.

Acebutolol


Icatibant may decrease the antihypertensive activities of Acebutolol.

Aceclofenac


The risk or severity of adverse effects can be increased when Icatibant is combined with Aceclofenac.

Advertisement

Acemetacin


The risk or severity of adverse effects can be increased when Icatibant is combined with Acemetacin.

Acenocoumarol


Icatibant may increase the anticoagulant activities of Acenocoumarol.

Acetyl salicylate


The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Icatibant.

Advertisement

Aclarubicin


Icatibant may decrease the excretion rate of Aclarubicin which could result in a higher serum level.

Adapalene


The risk or severity of adverse effects can be increased when Adapalene is combined with Icatibant.

Alclometasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Alclometasone.

Advertisement

Aldosterone


The risk or severity of adverse effects can be increased when Icatibant is combined with Aldosterone.

Alendronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Alendronic acid.

Alendronic acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Alendronic acid.

Aliskiren


Icatibant may decrease the antihypertensive activities of Aliskiren.

Alminoprofen


The risk or severity of adverse effects can be increased when Icatibant is combined with Alminoprofen.

Alprenolol


Icatibant may decrease the antihypertensive activities of Alprenolol.

Alprostadil


The therapeutic efficacy of Alprostadil can be decreased when used in combination with Icatibant.

Amcinonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Amcinonide.

Amikacin


Icatibant may decrease the excretion rate of Amikacin which could result in a higher serum level.

Amiloride


Icatibant may decrease the antihypertensive activities of Amiloride.

Ancrod


Icatibant may increase the anticoagulant activities of Ancrod.

Androstenedione


The risk or severity of adverse effects can be increased when Icatibant is combined with Androstenedione.

Anhydrous Tacrolimus


Tacrolimus may increase the immunosuppressive activities of Icatibant.

Anthrax immune globulin, human


The risk or severity of adverse effects can be increased when Icatibant is combined with Anthrax immune globulin human.

Antipyrine


The risk or severity of adverse effects can be increased when Antipyrine is combined with Icatibant.

Antithrombin III


Icatibant may increase the anticoagulant activities of Antithrombin III human.

Antithrombin III, Human


Icatibant may increase the anticoagulant activities of Antithrombin III human.

Apazone


The risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone.

Apixaban


Icatibant may increase the anticoagulant activities of Apixaban.

Apremilast


The risk or severity of adverse effects can be increased when Apremilast is combined with Icatibant.

Arbekacin


Icatibant may decrease the excretion rate of Arbekacin which could result in a higher serum level.

Ardeparin


Icatibant may increase the anticoagulant activities of Ardeparin.

Argatroban


Icatibant may increase the anticoagulant activities of Argatroban.

Argatroban Anhydrous


Icatibant may increase the anticoagulant activities of Argatroban.

Aspirin


The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Icatibant.

Atenolol


Icatibant may decrease the antihypertensive activities of Atenolol.

Azelastine


The risk or severity of adverse effects can be increased when Azelastine is combined with Icatibant.

azficel-T


The risk or severity of adverse effects can be increased when Icatibant is combined with Azficel-T.

Azilsartan


The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.

Azilsartan kamedoxomil


The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.

Azilsartan Medoxomil


The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.

Azosemide


The therapeutic efficacy of Azosemide can be decreased when used in combination with Icatibant.

Balsalazide


Icatibant may increase the nephrotoxic activities of Balsalazide.

BCG Vaccine


The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Icatibant.

BCG, Live, Connaught Strain


The risk or severity of adverse effects can be increased when Icatibant is combined with Bacillus calmette-guerin substrain connaught live antigen.

BCG, Live, Tice Strain


The risk or severity of adverse effects can be increased when Icatibant is combined with Bacillus calmette-guerin substrain tice live antigen.

Becaplermin


Icatibant may increase the anticoagulant activities of Becaplermin.

Beclomethasone Dipropionate


The risk or severity of adverse effects can be increased when Icatibant is combined with Beclomethasone dipropionate.

Benazepril


Icatibant may decrease the antihypertensive activities of Benazepril.

Bendroflumethiazide


The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Icatibant.

Benzydamine


The risk or severity of adverse effects can be increased when Icatibant is combined with Benzydamine.

Betamethasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Betamethasone.

Betaxolol


Icatibant may decrease the antihypertensive activities of Betaxolol.

Betrixaban


The risk or severity of bleeding can be increased when Betrixaban is combined with Icatibant.

Bimatoprost


The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Icatibant.

Bisoprolol


Icatibant may decrease the antihypertensive activities of Bisoprolol.

Bivalirudin


Icatibant may increase the anticoagulant activities of Bivalirudin.

Bopindolol


Icatibant may decrease the antihypertensive activities of Bopindolol.

Bromfenac


The risk or severity of adverse effects can be increased when Bromfenac is combined with Icatibant.

Budesonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Budesonide.

Bufexamac


The risk or severity of adverse effects can be increased when Icatibant is combined with Bufexamac.

Bumetanide


The therapeutic efficacy of Bumetanide can be decreased when used in combination with Icatibant.

Bupranolol


Icatibant may decrease the antihypertensive activities of Bupranolol.

Candesartan


The risk or severity of adverse effects can be increased when Candesartan is combined with Icatibant.

Candesartan Cilexetil


The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Icatibant.

Captopril


Icatibant may decrease the antihypertensive activities of Captopril.

Carboprost


The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Icatibant.

Carboprost Tromethamine


The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Icatibant.

Carprofen


The risk or severity of adverse effects can be increased when Carprofen is combined with Icatibant.

Carteolol


Icatibant may decrease the antihypertensive activities of Carteolol.

Carvedilol


Icatibant may decrease the antihypertensive activities of Carvedilol.

Celecoxib


The risk or severity of adverse effects can be increased when Icatibant is combined with Celecoxib.

Celiprolol


Icatibant may decrease the antihypertensive activities of Celiprolol.

Certoparin


Icatibant may increase the anticoagulant activities of Certoparin.

Chloroquine


The risk or severity of adverse effects can be increased when Chloroquine is combined with Icatibant.

Chlorothiazide


The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant.

Chlorthalidone


The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Icatibant.

Cholestyramine Resin


Cholestyramine can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.

Choline Magnesium Trisalicyclate


The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Icatibant.

Ciclesonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Ciclesonide.

Cilazapril


Icatibant may decrease the antihypertensive activities of Cilazapril.

Cinoxacin


Icatibant may increase the neuroexcitatory activities of Cinoxacin.

Citric Acid


Icatibant may increase the anticoagulant activities of Citric Acid.

Citric Acid, Anhydrous


Icatibant may increase the anticoagulant activities of Citric Acid.

Clobetasol


The risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasol.

Clobetasol Propionate


The risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasol propionate.

Clobetasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasone.

Clocortolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Clocortolone.

Clodronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Clodronic Acid.

Clonixin


The risk or severity of adverse effects can be increased when Icatibant is combined with Clonixin.

Colesevelam


Colesevelam can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.

Colestipol


Colestipol can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.

Cortisone Acetate


The risk or severity of adverse effects can be increased when Icatibant is combined with Cortisone acetate.

Curcumin


The risk or severity of adverse effects can be increased when Icatibant is combined with Curcumin.

Cyclopenthiazide


The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Icatibant.

Cyclosporine


Icatibant may increase the nephrotoxic activities of Cyclosporine.

Dabigatran Etexilate


Icatibant may increase the anticoagulant activities of Dabigatran etexilate.

Dalteparin


Icatibant may increase the anticoagulant activities of Dalteparin.

Danaparoid


Icatibant may increase the anticoagulant activities of Danaparoid.

Daunorubicin


Icatibant may decrease the excretion rate of Daunorubicin which could result in a higher serum level.

Deferasirox


The risk or severity of adverse effects can be increased when Icatibant is combined with Deferasirox.

Deflazacort


The risk or severity of adverse effects can be increased when Icatibant is combined with Deflazacort.

Denosumab


The risk or severity of adverse effects can be increased when Denosumab is combined with Icatibant.

Desirudin


Icatibant may increase the anticoagulant activities of Desirudin.

Desmopressin


The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.

Desonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Desonide.

Desoximetasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Desoximetasone.

Desoxycorticosterone acetate


The risk or severity of adverse effects can be increased when Icatibant is combined with Desoxycorticosterone acetate.

Desoxycorticosterone Pivalate


The risk or severity of adverse effects can be increased when Icatibant is combined with Desoxycorticosterone Pivalate.

Dexamethasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Dexamethasone.

Dexketoprofen


The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Icatibant.

Dextran


Icatibant may increase the anticoagulant activities of Dextran.

Dextran 40


Icatibant may increase the anticoagulant activities of Dextran 40.

Dextran 70


Icatibant may increase the anticoagulant activities of Dextran 70.

Dextran 75


Icatibant may increase the anticoagulant activities of Dextran 75.

Diclofenac


The risk or severity of adverse effects can be increased when Diclofenac is combined with Icatibant.

Dicumarol


Icatibant may increase the anticoagulant activities of Dicoumarol.

Diflorasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Diflorasone.

Diflucortolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Difluocortolone.

Diflunisal


The risk or severity of adverse effects can be increased when Diflunisal is combined with Icatibant.

Difluprednate


The risk or severity of adverse effects can be increased when Icatibant is combined with Difluprednate.

Digoxin


The serum concentration of Digoxin can be increased when it is combined with Icatibant.

Dihydrostreptomycin


Icatibant may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.

Dinoprost


The therapeutic efficacy of Dinoprost can be decreased when used in combination with Icatibant.

Dinoprost Tromethamine


The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Icatibant.

Dinoprostone


The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Icatibant.

Dipyrone


The risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant.

Doxorubicin


Icatibant may decrease the excretion rate of Doxorubicin which could result in a higher serum level.

Doxorubicin Hydrochloride


Icatibant may decrease the excretion rate of Doxorubicin which could result in a higher serum level.

Drospirenone


Icatibant may increase the hyperkalemic activities of Drospirenone.

Droxicam


The risk or severity of adverse effects can be increased when Icatibant is combined with Droxicam.

Edetic Acid


Icatibant may increase the anticoagulant activities of Edetic Acid.

Edoxaban


Icatibant may increase the anticoagulant activities of Edoxaban.

Enalapril


Icatibant may decrease the antihypertensive activities of Enalapril.

Enalaprilat


Icatibant may decrease the antihypertensive activities of Enalaprilat.

Enalaprilat Anhydrous


Icatibant may decrease the antihypertensive activities of Enalaprilat.

Enoxacin


Icatibant may increase the neuroexcitatory activities of Enoxacin.

Enoxaparin


Icatibant may increase the anticoagulant activities of Enoxaparin.

Enoxaparin sodium


Icatibant may increase the anticoagulant activities of Enoxaparin.

Epirubicin


Icatibant may decrease the excretion rate of Epirubicin which could result in a higher serum level.

Eplerenone


Icatibant may decrease the antihypertensive activities of Eplerenone.

Epoprostenol


The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Icatibant.

Eprosartan


The risk or severity of adverse effects can be increased when Eprosartan is combined with Icatibant.

Esmolol


Icatibant may decrease the antihypertensive activities of Esmolol.

Estrone


The risk or severity of adverse effects can be increased when Icatibant is combined with Estrone.

Etanercept


The risk or severity of adverse effects can be increased when Etanercept is combined with Icatibant.

Ethacrynate


The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Icatibant.

Ethacrynic Acid


The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Icatibant.

Ethylenediaminetetraacetate


Icatibant may increase the anticoagulant activities of Edetic Acid.

Etidronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Etidronic acid.

Etidronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Etidronic acid.

Etodolac


The risk or severity of adverse effects can be increased when Icatibant is combined with Etodolac.

Etofenamate


The risk or severity of adverse effects can be increased when Icatibant is combined with Etofenamate.

Etoricoxib


The risk or severity of adverse effects can be increased when Icatibant is combined with Etoricoxib.

Evening primrose oil


The risk or severity of adverse effects can be increased when Icatibant is combined with Evening primrose oil.

Felbinac


The risk or severity of adverse effects can be increased when Icatibant is combined with Felbinac.

Fenbufen


The risk or severity of adverse effects can be increased when Icatibant is combined with Fenbufen.

Fenoprofen


The risk or severity of adverse effects can be increased when Fenoprofen is combined with Icatibant.

Ferulic Acid


Icatibant may increase the anticoagulant activities of Ferulic acid.

Fingolimod


Icatibant may increase the immunosuppressive activities of Fingolimod.

Fleroxacin


Icatibant may increase the neuroexcitatory activities of Fleroxacin.

Floctafenine


The risk or severity of adverse effects can be increased when Floctafenine is combined with Icatibant.

Fludrocortisone


The risk or severity of adverse effects can be increased when Icatibant is combined with Fludrocortisone.

Fluindione


Icatibant may increase the anticoagulant activities of Fluindione.

Flumequine


Icatibant may increase the neuroexcitatory activities of Flumequine.

Flumethasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Flumethasone.

Flunisolide


The risk or severity of adverse effects can be increased when Icatibant is combined with Flunisolide.

Flunisolide Anhydrous (obsolete)


The risk or severity of adverse effects can be increased when Icatibant is combined with Flunisolide.

Fluocinolone Acetonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinolone Acetonide.

Fluocinonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinonide.

Fluocortolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocortolone.

Fluorometholone


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluorometholone.

FLUPREDNIDENE


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluprednidene.

Fluprednisolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluprednisolone.

Flurandrenolide


The risk or severity of adverse effects can be increased when Icatibant is combined with Flurandrenolide.

Flurbiprofen


The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Icatibant.

Fluticasone Furoate


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone furoate.

Fluticasone propionate


The risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone propionate.

Folate


The therapeutic efficacy of Folic Acid can be decreased when used in combination with Icatibant.

Folic Acid


The therapeutic efficacy of Folic Acid can be decreased when used in combination with Icatibant.

Fondaparinux


Icatibant may increase the anticoagulant activities of Fondaparinux.

Fondaparinux sodium


Icatibant may increase the anticoagulant activities of Fondaparinux sodium.

Formestane


The risk or severity of adverse effects can be increased when Icatibant is combined with Formestane.

Fosinopril


Icatibant may decrease the antihypertensive activities of Fosinopril.

Framycetin


Icatibant may decrease the excretion rate of Framycetin which could result in a higher serum level.

Furosemide


The therapeutic efficacy of Furosemide can be decreased when used in combination with Icatibant.

Gatifloxacin


Icatibant may increase the neuroexcitatory activities of Gatifloxacin.

Gatifloxacin Anhydrous


Icatibant may increase the neuroexcitatory activities of Gatifloxacin.

Gemeprost


The therapeutic efficacy of Gemeprost can be decreased when used in combination with Icatibant.

Gemifloxacin


Icatibant may increase the neuroexcitatory activities of Gemifloxacin.

Gemifloxacin Mesylate


Icatibant may increase the neuroexcitatory activities of Gemifloxacin.

Gentamicin


Icatibant may decrease the excretion rate of Gentamicin which could result in a higher serum level.

Grepafloxacin


Icatibant may increase the neuroexcitatory activities of Grepafloxacin.

Halcinonide


The risk or severity of adverse effects can be increased when Icatibant is combined with Halcinonide.

Halobetasol


The risk or severity of adverse effects can be increased when Icatibant is combined with Ulobetasol.

Haloperidol


The risk or severity of adverse effects can be increased when Icatibant is combined with Haloperidol.

Heparin


Icatibant may increase the anticoagulant activities of Heparin.

Hepatitis A Vaccine, Inactivated


The risk or severity of adverse effects can be increased when Icatibant is combined with Hepatitis A Vaccine.

Hepatitis B Surface Antigen Vaccine


The risk or severity of adverse effects can be increased when Icatibant is combined with Hepatitis B Vaccine (Recombinant).

Hydralazine


Icatibant may decrease the antihypertensive activities of Hydralazine.

Hydrochlorothiazide


The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Icatibant.

Hydrocortisone


The risk or severity of adverse effects can be increased when Icatibant is combined with Hydrocortisone.

Hydroflumethiazide


The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Icatibant.

Ibandronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.

Ibandronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.

Ibuprofen


The risk or severity of adverse effects can be increased when Ibuprofen is combined with Icatibant.

Idarubicin


Icatibant may decrease the excretion rate of Idarubicin which could result in a higher serum level.

Iloprost


The therapeutic efficacy of Iloprost can be decreased when used in combination with Icatibant.

Imidapril


Icatibant may decrease the antihypertensive activities of Imidapril.

Indapamide


The therapeutic efficacy of Indapamide can be decreased when used in combination with Icatibant.

Indobufen


The risk or severity of adverse effects can be increased when Icatibant is combined with Indobufen.

Indomethacin


The risk or severity of adverse effects can be increased when Indomethacin is combined with Icatibant.

Irbesartan


The risk or severity of adverse effects can be increased when Irbesartan is combined with Icatibant.

Kanamycin


Icatibant may decrease the excretion rate of Kanamycin which could result in a higher serum level.

kanamycin A


Icatibant may decrease the excretion rate of Kanamycin which could result in a higher serum level.

Kebuzone


The risk or severity of adverse effects can be increased when Icatibant is combined with Kebuzone.

Ketoprofen


The risk or severity of adverse effects can be increased when Ketoprofen is combined with Icatibant.

Ketorolac


The risk or severity of adverse effects can be increased when Ketorolac is combined with Icatibant.

Labetalol


Icatibant may decrease the antihypertensive activities of Labetalol.

Latanoprost


The therapeutic efficacy of Latanoprost can be decreased when used in combination with Icatibant.

Latanoprostene Bunod


The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Icatibant.

Leflunomide


The risk or severity of adverse effects can be increased when Icatibant is combined with Leflunomide.

Lepirudin


Icatibant may increase the anticoagulant activities of Lepirudin.

Levobunolol


Icatibant may decrease the antihypertensive activities of Levobunolol.

Levofloxacin


Icatibant may increase the neuroexcitatory activities of Levofloxacin.

Levofloxacin Anhydrous


Icatibant may increase the neuroexcitatory activities of Levofloxacin.

Limonene, (+)-


The risk or severity of adverse effects can be increased when Icatibant is combined with (4R)-limonene.

Lisinopril


Icatibant may decrease the antihypertensive activities of Lisinopril.

Lisinopril Anhydrous


Icatibant may decrease the antihypertensive activities of Lisinopril.

Lithium


The serum concentration of Lithium can be increased when it is combined with Icatibant.

Lithium Cation


The serum concentration of Lithium can be increased when it is combined with Icatibant.

Lornoxicam


The risk or severity of adverse effects can be increased when Icatibant is combined with Lornoxicam.

Losartan


The risk or severity of adverse effects can be increased when Losartan is combined with Icatibant.

Loteprednol


The risk or severity of adverse effects can be increased when Icatibant is combined with Loteprednol.

Loxoprofen


The risk or severity of adverse effects can be increased when Icatibant is combined with Loxoprofen.

Lubiprostone


The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Icatibant.

Magnesium Salicylate


The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icatibant.

Masoprocol


The risk or severity of adverse effects can be increased when Masoprocol is combined with Icatibant.

Meclofenamate


The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.

Meclofenamic Acid


The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.

Medronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Technetium Tc-99m medronate.

Medrysone


The risk or severity of adverse effects can be increased when Icatibant is combined with Medrysone.

Mefenamic Acid


The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icatibant.

Meloxicam


The risk or severity of adverse effects can be increased when Meloxicam is combined with Icatibant.

Mesalamine


Icatibant may increase the nephrotoxic activities of Mesalazine.

Methotrexate


The serum concentration of Methotrexate can be increased when it is combined with Icatibant.

Methyclothiazide


The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icatibant.

Methylprednisolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Methylprednisolone.

Metipranolol


Icatibant may decrease the antihypertensive activities of Metipranolol.

Metolazone


The therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant.

Metoprolol


Icatibant may decrease the antihypertensive activities of Metoprolol.

Metrizamide


Icatibant may decrease the excretion rate of Metrizamide which could result in a higher serum level.

Misoprostol


The therapeutic efficacy of Misoprostol can be decreased when used in combination with Icatibant.

Moexipril


Icatibant may decrease the antihypertensive activities of Moexipril.

Mometasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Mometasone.

Morniflumate


The risk or severity of adverse effects can be increased when Morniflumate is combined with Icatibant.

MYCOPHENOLATE


The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.

Mycophenolate Mofetil


The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icatibant.

Mycophenolic Acid


The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.

Nabumetone


The risk or severity of adverse effects can be increased when Icatibant is combined with Nabumetone.

Nadolol


Icatibant may decrease the antihypertensive activities of Nadolol.

Nadroparin


Icatibant may increase the anticoagulant activities of Nadroparin.

Naftifine


The risk or severity of adverse effects can be increased when Naftifine is combined with Icatibant.

Nalidixic Acid


Icatibant may increase the neuroexcitatory activities of Nalidixic Acid.

Naproxen


The risk or severity of adverse effects can be increased when Naproxen is combined with Icatibant.

Natalizumab


The risk or severity of adverse effects can be increased when Icatibant is combined with Natalizumab.

Nebivolol


Icatibant may decrease the antihypertensive activities of Nebivolol.

Neomycin


Icatibant may decrease the excretion rate of Neomycin which could result in a higher serum level.

Nepafenac


The risk or severity of adverse effects can be increased when Nepafenac is combined with Icatibant.

Netilmicin


Icatibant may decrease the excretion rate of Netilmicin which could result in a higher serum level.

Niflumic Acid


The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icatibant.

Nimesulide


The risk or severity of adverse effects can be increased when Nimesulide is combined with Icatibant.

Norfloxacin


Icatibant may increase the neuroexcitatory activities of Norfloxacin.

Ocrelizumab


Ocrelizumab may increase the immunosuppressive activities of Icatibant.

Oenothera biennis seed extract


The risk or severity of adverse effects can be increased when Icatibant is combined with Evening primrose oil.

Olmesartan


The risk or severity of adverse effects can be increased when Olmesartan is combined with Icatibant.

Olopatadine


The risk or severity of adverse effects can be increased when Olopatadine is combined with Icatibant.

Olsalazine


Icatibant may increase the nephrotoxic activities of Olsalazine.

Omacetaxine Mepesuccinate


The risk or severity of bleeding can be increased when Icatibant is combined with Omacetaxine mepesuccinate.

Oxaprozin


The risk or severity of adverse effects can be increased when Oxaprozin is combined with Icatibant.

Oxprenolol


Icatibant may decrease the antihypertensive activities of Oxprenolol.

Oxyphenbutazone


The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icatibant.

Pamidronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Pamidronate.

Pamidronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Pamidronate.

Paramethasone


The risk or severity of adverse effects can be increased when Icatibant is combined with Paramethasone.

Parecoxib


The risk or severity of adverse effects can be increased when Icatibant is combined with Parecoxib.

Paromomycin


Icatibant may decrease the excretion rate of Paromomycin which could result in a higher serum level.

Parthenolide


The risk or severity of adverse effects can be increased when Icatibant is combined with Parthenolide.

Pefloxacin


Icatibant may increase the neuroexcitatory activities of Pefloxacin.

Penbutolol


Icatibant may decrease the antihypertensive activities of Penbutolol.

Pentaerythritol Tetranitrate


Icatibant may increase the anticoagulant activities of Pentaerythritol Tetranitrate.

Pentosan Polysulfate


Icatibant may increase the anticoagulant activities of Pentosan Polysulfate.

Perindopril


Icatibant may decrease the antihypertensive activities of Perindopril.

Phenindione


Icatibant may increase the anticoagulant activities of Phenindione.

Phenprocoumon


Icatibant may increase the anticoagulant activities of Phenprocoumon.

Phenylbutazone


The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Icatibant.

Pimecrolimus


The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icatibant.

Pindolol


Icatibant may decrease the antihypertensive activities of Pindolol.

Pirarubicin


Icatibant may decrease the excretion rate of Pirarubicin which could result in a higher serum level.

Piretanide


The therapeutic efficacy of Piretanide can be decreased when used in combination with Icatibant.

Pirfenidone


The risk or severity of adverse effects can be increased when Pirfenidone is combined with Icatibant.

Piroxicam


The risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.

Piroxicam-Beta-Cyclodextrin


The risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.

Plicamycin


Icatibant may decrease the excretion rate of Plicamycin which could result in a higher serum level.

Polythiazide


The therapeutic efficacy of Polythiazide can be decreased when used in combination with Icatibant.

Practolol


Icatibant may decrease the antihypertensive activities of Practolol.

Pralatrexate


The serum concentration of Pralatrexate can be increased when it is combined with Icatibant.

Prasterone


The risk or severity of adverse effects can be increased when Icatibant is combined with Prasterone.

Prednicarbate


The risk or severity of adverse effects can be increased when Icatibant is combined with Prednicarbate.

Prednisolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Prednisolone.

Prednisone


The risk or severity of adverse effects can be increased when Icatibant is combined with Prednisone.

Pregnenolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Pregnenolone.

Probenecid


The serum concentration of Icatibant can be increased when it is combined with Probenecid.

Propranolol


Icatibant may decrease the antihypertensive activities of Propranolol.

protein C, human


Icatibant may increase the anticoagulant activities of Protein C.

protein S, human


Icatibant may increase the anticoagulant activities of Protein S human.

Protocatechualdehyde


Icatibant may increase the anticoagulant activities of Protocatechualdehyde.

Quinapril


Icatibant may decrease the antihypertensive activities of Quinapril.

Quinethazone


The therapeutic efficacy of Quinethazone can be decreased when used in combination with Icatibant.

Rabies Immune Globulin, Human


The risk or severity of adverse effects can be increased when Icatibant is combined with Human rabies virus immune globulin.

Rabies Virus Vaccine Flury-Lep Strain


The risk or severity of adverse effects can be increased when Icatibant is combined with Rabies virus inactivated antigen, A.

Ramipril


Icatibant may decrease the antihypertensive activities of Ramipril.

Rescinnamine


Icatibant may decrease the antihypertensive activities of Rescinnamine.

Resveratrol


The risk or severity of adverse effects can be increased when Resveratrol is combined with Icatibant.

Reviparin


Icatibant may increase the anticoagulant activities of Reviparin.

Reviparin sodium


Icatibant may increase the anticoagulant activities of Reviparin.

Rimexolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Rimexolone.

Risedronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.

Risedronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.

Rivaroxaban


Icatibant may increase the anticoagulant activities of Rivaroxaban.

Rofecoxib


The risk or severity of adverse effects can be increased when Icatibant is combined with Rofecoxib.

Roflumilast


Roflumilast may increase the immunosuppressive activities of Icatibant.

Rosoxacin


Icatibant may increase the neuroexcitatory activities of Rosoxacin.

ROTAVIRUS VACCINE, LIVE


The risk or severity of adverse effects can be increased when Icatibant is combined with Rotavirus Vaccine.

Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)


The risk or severity of adverse effects can be increased when Icatibant is combined with Rubella virus vaccine.

Sacubitril


The risk or severity of adverse effects can be increased when Sacubitril is combined with Icatibant.

Salicylamide


The risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide.

Salicylic Acid


The risk or severity of adverse effects can be increased when Salicylic acid is combined with Icatibant.

Salmonella enterica subsp. enterica serovar typhi


The risk or severity of adverse effects can be increased when Icatibant is combined with Salmonella typhi ty21a live antigen.

Salsalate


The risk or severity of adverse effects can be increased when Salsalate is combined with Icatibant.

Saralasin


The risk or severity of adverse effects can be increased when Saralasin is combined with Icatibant.

Sarilumab


Sarilumab may increase the immunosuppressive activities of Icatibant.

Serratiopeptidase


The risk or severity of adverse effects can be increased when Icatibant is combined with Serrapeptase.

sipuleucel-T


The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Icatibant.

Sisomicin


Icatibant may decrease the excretion rate of Sisomicin which could result in a higher serum level.

Sodium Phosphate


Sodium phosphate may increase the nephrotoxic activities of Icatibant.

Sodium Phosphate, Monobasic


Sodium phosphate may increase the nephrotoxic activities of Icatibant.

SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS


Sodium phosphate may increase the nephrotoxic activities of Icatibant.

Sotalol


Icatibant may decrease the antihypertensive activities of Sotalol.

Sparfloxacin


Icatibant may increase the neuroexcitatory activities of Sparfloxacin.

Spectinomycin


Icatibant may decrease the excretion rate of Spectinomycin which could result in a higher serum level.

Spirapril


Icatibant may decrease the antihypertensive activities of Spirapril.

Spironolactone


Icatibant may decrease the antihypertensive activities of Spironolactone.

Streptomycin


Icatibant may decrease the excretion rate of Streptomycin which could result in a higher serum level.

Streptozocin


Icatibant may decrease the excretion rate of Streptozocin which could result in a higher serum level.

Sulfasalazine


The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Icatibant.

Sulindac


The risk or severity of adverse effects can be increased when Sulindac is combined with Icatibant.

Suprofen


The risk or severity of adverse effects can be increased when Suprofen is combined with Icatibant.

Tacrolimus


Tacrolimus may increase the immunosuppressive activities of Icatibant.

Tafluprost


The therapeutic efficacy of Tafluprost can be decreased when used in combination with Icatibant.

Talinolol


Icatibant may decrease the antihypertensive activities of Talinolol.

Talniflumate


The risk or severity of adverse effects can be increased when Talniflumate is combined with Icatibant.

Technetium Tc 99m Medronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Technetium Tc-99m medronate.

Telmisartan


The risk or severity of adverse effects can be increased when Telmisartan is combined with Icatibant.

Temafloxacin


Icatibant may increase the neuroexcitatory activities of Temafloxacin.

Tenofovir Disoproxil


The risk or severity of adverse effects can be increased when Icatibant is combined with Tenofovir disoproxil.

Tenoxicam


The risk or severity of adverse effects can be increased when Tenoxicam is combined with Icatibant.

Teriflunomide


The risk or severity of adverse effects can be increased when Icatibant is combined with Teriflunomide.

Tetanus Toxoid Vaccine, Inactivated


The risk or severity of adverse effects can be increased when Icatibant is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).

Tiaprofenic Acid


The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icatibant.

Tiludronate


The risk or severity of adverse effects can be increased when Icatibant is combined with Tiludronic acid.

Tiludronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Tiludronic acid.

Timolol


Icatibant may decrease the antihypertensive activities of Timolol.

Timolol Anhydrous


Icatibant may decrease the antihypertensive activities of Timolol.

Tixocortol


The risk or severity of adverse effects can be increased when Icatibant is combined with Tixocortol.

Tobramycin


Icatibant may decrease the excretion rate of Tobramycin which could result in a higher serum level.

Tofacitinib


Icatibant may increase the immunosuppressive activities of Tofacitinib.

Tolfenamic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Tolfenamic Acid.

Tolmetin


The risk or severity of adverse effects can be increased when Tolmetin is combined with Icatibant.

Torsemide


The therapeutic efficacy of Torasemide can be decreased when used in combination with Icatibant.

Trandolapril


Icatibant may decrease the antihypertensive activities of Trandolapril.

Tranilast


The risk or severity of adverse effects can be increased when Icatibant is combined with Tranilast.

Trastuzumab


Trastuzumab may increase the neutropenic activities of Icatibant.

Travoprost


The therapeutic efficacy of Travoprost can be decreased when used in combination with Icatibant.

Treprostinil


The risk or severity of adverse effects can be increased when Treprostinil is combined with Icatibant.

Triamcinolone


The risk or severity of adverse effects can be increased when Icatibant is combined with Triamcinolone.

Triamterene


Icatibant may decrease the antihypertensive activities of Triamterene.

Trichlormethiazide


The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Icatibant.

Trovafloxacin


Icatibant may increase the neuroexcitatory activities of Trovafloxacin.

Troxerutin


Icatibant may increase the anticoagulant activities of Troxerutin.

Typhoid Vaccine Live Ty21a


The risk or severity of adverse effects can be increased when Icatibant is combined with Salmonella typhi ty21a live antigen.

Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain


The risk or severity of adverse effects can be increased when Icatibant is combined with Salmonella typhi ty2 vi polysaccharide antigen.

UNOPROSTONE


The therapeutic efficacy of Unoprostone can be decreased when used in combination with Icatibant.

Valdecoxib


The risk or severity of adverse effects can be increased when Icatibant is combined with Valdecoxib.

Valrubicin


Icatibant may decrease the excretion rate of Valrubicin which could result in a higher serum level.

Valsartan


The risk or severity of adverse effects can be increased when Valsartan is combined with Icatibant.

Vancomycin


The serum concentration of Vancomycin can be increased when it is combined with Icatibant.

Varicella Virus Vaccine Live (Oka-Merck) strain


The risk or severity of adverse effects can be increased when Icatibant is combined with Varicella Zoster Vaccine (Live/Attenuated).

Warfarin


Icatibant may increase the anticoagulant activities of Warfarin.

Yellow Fever Vaccine


The risk or severity of adverse effects can be increased when Icatibant is combined with Yellow Fever Vaccine.

Yellow-Fever Virus Vaccine, 17D-204 strain


The risk or severity of adverse effects can be increased when Icatibant is combined with Yellow Fever Vaccine.

Zileuton


The risk or severity of adverse effects can be increased when Zileuton is combined with Icatibant.

Zofenopril


Icatibant may decrease the antihypertensive activities of Zofenopril.

Zoledronic Acid


The risk or severity of adverse effects can be increased when Icatibant is combined with Zoledronic acid.

Zoledronic Acid Anhydrous


The risk or severity of adverse effects can be increased when Icatibant is combined with Zoledronic acid.

Zomepirac


The risk or severity of adverse effects can be increased when Zomepirac is combined with Icatibant.

Advertisement
Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Ultimate Weight Loss Handbook: A Complete Guide to Achieving Your Goals
Stay Connected
Available on the Android Market Available on the App Store